Analyst Estimates: Here's What Brokers Think Of Pharma Mar, S.A. (BME:PHM) After Its Half-Yearly Report

Last week saw the newest half-yearly earnings release from Pharma Mar, S.A. (BME:PHM), an important milestone in the company's journey to build a stronger business. Overall the results were a little better than the analysts were expecting, with revenues beating forecasts by 3.8%to hit €93m. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Taking into account the latest results, Pharma Mar's nine analysts currently expect revenues in 2026 to be €218.7m, approximately in line with the last 12 months. Before this earnings report, the analysts had been forecasting revenues of €215.6m and earnings per share (EPS) of €2.32 in 2026. Overall, while the analysts have reconfirmed their revenue estimates, the consensus now no longer provides an EPS estimate. This implies that the market believes revenue is more important after these latest results.

View our latest analysis for Pharma Mar

We'd also point out that thatthe analysts have made no major changes to their price target of €104. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. There are some variant perceptions on Pharma Mar, with the most bullish analyst valuing it at €125 and the most bearish at €85.50 per share. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. From these estimates it looks as though the analysts expect the years of declining revenue to come to an end, given the flat forecast out to 2026. That would be a definite improvement, given that the past five years have seen revenue shrink 1.7% annually. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 15% annually. So it's pretty clear that, although revenues are improving, Pharma Mar is still expected to grow slower than the industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their revenue estimates for next year, suggesting that the business is performing in line with expectations. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

At least one of Pharma Mar's nine analysts has provided estimates out to 2028, which can be seen for free on our platform here.

However, before you get too enthused, we've discovered 1 warning sign for Pharma Mar that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.